Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-PROT-101

ABSTRACT: Biomarkers discovery for Colorectal cancer

PROVIDER: E-PROT-101 | ExpressionAtlas | 2023-06-21

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-PROT-101-MappedToGeneID.txt	Txt
	E-PROT-101-MaxQuant_Summary_ExpressionAtlas_LabelFree_Rmarkdown.pdf	Pdf
	E-PROT-101-analysis-methods.tsv	Tabular
	E-PROT-101-configuration.xml	Xml
	E-PROT-101-factors.xml	Xml

Items per page:

1 - 5 of 11

Similar Datasets

E-PROT-100

Project description:Biomarkers discovery for Colorectal cancer liver metastasis

2023-06-21 | E-PROT-100 | ExpressionAtlas

Tissue and blood microRNA array profiles of colorectal cancer patients

Project description:microRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs offer great potential as cancer biomarkers. The objective of the study was to correlate the differential expression of miRNAs in tissue and blood in the identification of biomarkers for early detection of colorectal cancer (CRC). miRNA biomarker discovery via miRNA array profiling using paired cancer tissues (n = 30) and blood samples (CRC, n = 42; control, n = 18).

2013-12-30 | E-GEOD-39845 | biostudies-arrayexpress

Methylation analysis of serum cfDNA pooled samples for the discovery of non-invasive biomarkers for colorectal cancer

Project description:We explored the differential methylation patterns found in cfDNA between no neoplasia (NN; individuals with no colorectal findings, benign pathologies and non-advanced adenomas) and patients with advanced neoplasia (AN; advanced adenomas and colorectal cancer) using pooled samples, for the discovery of non-invasive methylation biomarkers for CRC screening. cfDNA was extracted from serum samples and methylation measurements were assessed with the Infinium MethylationEPIC BeadChip. Data was mainly preprocessed and analyzed with R/Bioconductor packages.

2023-10-01 | GSE186381 | GEO

5-hydroxymethylcytosine marks promoters in colon that resist hypermethylation in cancer [seq]

Project description:The discovery of cytosine hydroxymethylation (5-hmC) as a mechanism that potentially controls DNA methylation changes typical of neoplasia prompted us to investigate its behavior in colon cancer. 5-hmC is globally reduced in proliferating cells such as colon tumors and the gut crypt progenitors, from which tumors can arise. Here, we show that colorectal tumors and cancer cells express Ten-Eleven Translocation (TET) transcripts at levels similar to normal tissues. Genome-wide analyses show that promoters marked by 5-hmC in normal tissue, and those identified as TET2 targets in colorectal cancer cells, are resistant to methylation gain in cancer. In vitro studies of TET2 in cancer cells confirm that these promoters are resistant to methylation gain independently of sustained TET2 expression. We also find that a considerable number of the methylation gain-resistant promoters marked by 5-hmC in normal colon overlap with those that are marked with poised bivalent histone modifications in embryonic stem cells. Together our results indicate that promoters that acquire 5-hmC upon normal colon differentiation are innately resistant to neoplastic hypermethylation by mechanisms that do not require high levels of 5-hmC in tumors. Our study highlights the potential of cytosine modifications as biomarkers of cancerous cell proliferation. 5 normal colon samples and 4 matching tumor samples were profiled for 5-hydroxymethylcytosine content genomewide using hmeDIP-seq. The colorectal cancer cell line HCT116 was profiled for binding of TET2 genomewide by chromatin immunoprecipitation sequencing (ChIP-seq).

2015-02-03 | E-GEOD-47590 | biostudies-arrayexpress

Discovery of lncRNA biomarkers of prostate cancer

Project description:Discovery of lncRNA biomarkers of prostate cancer

| PRJNA474912 | ENA

E-PROT-107

Project description:Identification and validation of stage-associated serum biomarkers in colorectal cancer stages.

2023-06-21 | E-PROT-107 | ExpressionAtlas

Homo sapiens

Project description:Discovery of salivary transcriptomic biomarkers for ovarian cancer

| PRJNA140075 | ENA

Transcription profiling of rectal adenocarcinomas biopsied before and after pre-operative short-course radiotherapy or 5-flurouracil-based chemoradiotherapy

Project description:The molecular mechanisms of clinical response or resistance to therapy were evaluated in colorectal cancer patients in a prospective biomarker discovery project. Rectal adenocarcinomas, biopsied before (diagnostic biopsy) and after (surgical resection) pre-operative short-course radiotherapy [RT] or 5-flurouracil (5-FU)-based chemoradiotherapy [CRT], were profiled using Affymetrix HGU133 Plus 2.0 microarrays. Tumour tissues from untreated controls at diagnosis and surgical resection were used to identify treatment-independent gene expression changes. Candidate resistance biomarkers were identified in this pilot study for validation in a larger cohort.

2009-11-10 | E-MEXP-1901 | biostudies-arrayexpress

DNA Methylation Biomarkers for Noninvasive Diagnosis of Colorectal Cancer

Project description:DNA methylation in colorectal cancer diagnosis. The Illumina GoldenGate Methylation Cancer Panel I was used to select a set of candidates markers informative of colorectal cancer diagnosis from 807 cancer-related genes. In the discovery phase, tumor tissue and paired adjacent normal mucosa from 92 colorectal patients were analyzed.

2013-05-27 | GSE43369 | GEO

Tissue and blood microRNA array profiles of colorectal cancer patients

2013-12-30 | GSE39845 | GEO